Funded in part by Eli Lilly and Company, Sanofi, Insulet Corporation, Nipro, Roche Diabetes Care, Abbott Diabetes Care
Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes
Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD, DCCT/EDIC Research Group
Diabetes technology & therapeutics · 15 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Eli Lilly and Company
- Company
- Sanofi
- Nonprofit
- Heart and Stroke Foundation of Canada
- Government
- Genome Canada
- Government
- Ontario Genomics
- Company
- Insulet Corporation
- Company
- Nipro
- Government
- Ontario Genomics Institute
- Company
- Roche Diabetes Care
- Government
- National Institutes of Health
- Company
- Abbott Diabetes Care
- Government
- National Eye Institute
- Government
- National Institute of Diabetes and Digestive and Kidney Diseases
- Government
- NIDDK NIH HHS
- Authors
- At least one author declares a financial tie to industry
- Grants
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-094176); National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK077510); National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020595); National Institute of Diabetes and Digestive and Kidney Diseases (P60DK20595); National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK094176 and U01 DK094157); National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK094157); National Institute of Diabetes and Digestive and Kidney Diseases (R37 DK034818); National Institute of Diabetes and Digestive and Kidney Diseases (DK-34818); National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK077489); National Institute of Diabetes and Digestive and Kidney Diseases (N01‐DK‐6‐2204); National Institutes of Health (U01-DK- 094157); National Institutes of Health (P60 DK20595); National Institutes of Health (U01-DK-094176); National Institutes of Health (DK094157); National Institutes of Health (DK094176)
Based on 14 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2015-07-20 · Diabetes Technol Ther · vol. 17 · issue 10 · pp. 726–734
- Publisher
- Mary Ann Liebert, Inc.
- Cited
- 50 citations · more than 86% of similar papers · 2.2× the field average
- References
- 45 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Coffee research and impacts · Advanced Glycation End Products research · Circadian rhythm and melatonin
- Keywords
- Medicine, Diabetes mellitus, Type 2 diabetes, Caffeine, Consumption (sociology), Type 1 diabetes, Fluorescence, Endocrinology, Optics
- MeSH
- skin, humans, diabetes mellitus, type 1, caffeine, arylamine n-acetyltransferase, genotype, fluorescence, coffee, adolescent, adult, female, male, young adult, glycation end products, advanced
9 authors
From GB, CA, US
- Karen M. EnyGreat Ormond Street Hospital; Hospital for Sick Children; SickKids Foundation; University College London
- Trevor John OrchardUniversity of Pittsburgh
- Rachel G. MillerUniversity of Pittsburgh
- John MaynardnLIGHT (United States)
- Denis M. GrantUniversity of Toronto
- Tina CostacouUniversity of Pittsburgh
Abstract
Background
A variant (rs1495741) in the gene for the N-acetyltransferase 2 (NAT2) protein is associated with skin intrinsic fluorescence (SIF), a noninvasive measure of advanced glycation end products and other fluorophores in the skin. Because NAT2 is involved in caffeine metabolism, we aimed to determine whether caffeine consumption is associated with SIF and whether rs1495741 is associated with SIF independently of caffeine.
Materials and methods
SIF was measured in 1,181 participants with type 1 diabetes from the Epidemiology of Diabetes Interventions and Complications study. Two measures of SIF were used: SIF1, using a 375-nm excitation light-emitting diode (LED), and SIF14 (456-nm LED). Food frequency questionnaires were used to estimate mean caffeine intake. To establish replication, we examined a second type 1 diabetes cohort.
Results
Higher caffeine intake was significantly associated with higher SIF1(LED 375 nm[0.6, 0.2]) (P=2×10(-32)) and SIF14L(ED 456 nm[0.4, 0.8]) (P=7×10(-31)) and accounted for 4% of the variance in each after adjusting for covariates. When analyzed together, caffeine intake and rs1495741 both remained highly significantly associated with SIF1(LED 375 nm[0.6, 0.2]) and SIF14(LED 456 nm[0.4, 0.8]). Mean caffeinated coffee intake was also positively associated with SIF1(LED 375 nm[0.6, 0.2]) (P=9×10(-12)) and SIF14(LED 456 nm[0.4, 0.8]) (P=4×10(-12)), but no association was observed for decaffeinated coffee intake. Finally, caffeine was also positively associated with SIF1(LED 375 nm[0.6, 0.2]) and SIF14(LED 456 nm[0.4, 0.8]) (P<0.0001) in the replication cohort.
Conclusions
Caffeine contributes to SIF. The effect of rs1495741 on SIF appears to be partially independent of caffeine consumption. Because SIF and coffee intake are each associated with cardiovascular disease, our findings suggest that accounting for coffee and/or caffeine intake may improve risk prediction models for SIF and cardiovascular disease in individuals with diabetes.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.